Cardinal Health is a Dublin, Ohio-based pharmaceutical and medical products distributor that serves the majority of U.S. hospitals, pharmacies, and healthcare providers, and the company is in the middle of a fiscal year that demonstrates the kind of diversification the pharmaceutical distribution cohort has been waiting for. Fiscal fourth quarter 2026 total revenue of $60.0 billion was 14 percent above the prior-year quarter, and the Pharma and Specialty Solutions segment revenue of $56.0 billion was 15 percent above the prior year. The company is now generating a meaningful growth contribution from the GLP-1 medication distribution franchise and the broader specialty pharmaceutical franchise, and the diversification is the cleanest single-sentence read on what the pharmaceutical distribution business model is producing in a post-pandemic healthcare environment.
The numbers tell the story with the kind of operational detail that the healthcare distribution equity has been waiting for. The fiscal 2026 full-year revenue was driven by 15 percent growth in the Pharma segment from existing and new customers, and the Global Medical Products and Distribution segment revenue was relatively flat year over year. The fiscal fourth quarter 2026 revenue growth was driven by the same factors, and the growth is the structural feature the company has been producing. The cash position at quarter-end of $4.9 billion, the $13.8 billion in trade receivables, and the $17.3 billion in inventory are the structural features the equity offers the buy-side.
The dividend at the parent level has been steadily increasing in recent years, and the dividend yield at the current share price is the second structural feature the equity offers the buy-side. The 1.3 times price-to-book multiple is the third structural feature, and the multiple is the source of the valuation the market is producing for the equity.
The question the next four quarters resolve is whether the company can sustain the Pharma segment growth and the diversification through the GLP-1 demand moderation the company has explicitly disclosed, and whether the post-pandemic healthcare environment remains favorable. A fiscal 2027 first-quarter print that shows Pharma segment growth continuing at the high-single-digit to low-double-digit pace would confirm the diversification is producing. A first-quarter print that shows Pharma segment growth decelerating below 5 percent would force the market to reprice the equity for a more modest terminal value.